Preemptive azacitidine treatment guided by measurable residual disease (MRD) status was associated with delayed relapse in patients with myelodysplastic neoplasms or acute myeloid leukemia (AML), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results